Assessing the Efficacy and Safety of an 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor (AZD4017) in the Idiopathic Intracranial Hypertension Drug Trial, IIH:DT: Clinical Methods and Design for a Phase II Randomized Controlled Trial

Assessing the Efficacy and Safety of an 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor (AZD4017) in the Idiopathic Intracranial Hypertension Drug Trial, IIH:DT: Clinical Methods and Design for a Phase II Randomized Controlled Trial

Authors of this article:

Keira Annie Markey^{1, 2} ;   Ryan Ottridge³ ;   James L Mitchell^{1, 2} ;   Caroline Rick³ ;   Rebecca Woolley³ ;   Natalie Ives³ ;   Peter Nightingale⁴ ;   Alexandra J Sinclair^{1, 2}